Abstract
Chemotherapy-Induced Nausea and Vomiting.
Highlights
Over the last decade, the discovery of the neurokinin-1 receptor antagonists (NK1-RA) and its role in the pathogenesis of delayed phase of chemotherapy-induced nausea and vomiting (CINV) has led to significant developments in the management of this complication of anticancer treatment
Improvements in the management of CINV control were achieved with the discovery of 5hydroxytryptamine (5HT3) receptor and the development of 5HT3 receptor antagonists (RA)
The discovery of the neurokinin-1 receptor antagonists (NK1-RA) and its role in the pathogenesis of delayed phase of CINV has led to significant developments in the management of this complication of anticancer treatment
Summary
Improvements in the management of CINV control were achieved with the discovery of 5hydroxytryptamine (5HT3) receptor and the development of 5HT3 receptor antagonists (RA). The discovery of the neurokinin-1 receptor antagonists (NK1-RA) and its role in the pathogenesis of delayed phase of CINV has led to significant developments in the management of this complication of anticancer treatment. Seventy percent of patients treated with cisplatin-based HEC will achieve an overall antiemetic complete response when managed with a triple therapy consisting of a NK1 RA aprepitant in combination with a 5HT3 RA and corticosteroids prophylaxis [4, 5].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
